Cue Biopharma, Inc. (NASDAQ:CUE) Shares Acquired by Barclays PLC

Barclays PLC raised its holdings in Cue Biopharma, Inc. (NASDAQ:CUE) by 85.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,730 shares of the company’s stock after acquiring an additional 11,388 shares during the quarter. Barclays PLC owned 0.08% of Cue Biopharma worth $302,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of CUE. Morgan Stanley lifted its holdings in Cue Biopharma by 125.7% in the 4th quarter. Morgan Stanley now owns 544,062 shares of the company’s stock valued at $6,806,000 after acquiring an additional 302,995 shares during the last quarter. Advisory Research Inc. acquired a new stake in Cue Biopharma in the 1st quarter valued at about $3,123,000. Sanders Morris Harris LLC lifted its holdings in Cue Biopharma by 82.1% in the 1st quarter. Sanders Morris Harris LLC now owns 352,534 shares of the company’s stock valued at $4,385,000 after acquiring an additional 158,943 shares during the last quarter. BlackRock Inc. lifted its holdings in Cue Biopharma by 3.9% in the 1st quarter. BlackRock Inc. now owns 2,247,704 shares of the company’s stock valued at $27,422,000 after acquiring an additional 84,726 shares during the last quarter. Finally, Carlson Capital L P lifted its holdings in Cue Biopharma by 81.9% in the 1st quarter. Carlson Capital L P now owns 154,600 shares of the company’s stock valued at $1,886,000 after acquiring an additional 69,600 shares during the last quarter. 59.72% of the stock is owned by institutional investors.

NASDAQ CUE opened at $11.13 on Thursday. The business’s 50-day moving average is $12.70. The firm has a market cap of $349.63 million, a P/E ratio of -7.42 and a beta of 1.79. Cue Biopharma, Inc. has a 1 year low of $9.86 and a 1 year high of $22.49.

Cue Biopharma (NASDAQ:CUE) last posted its quarterly earnings data on Monday, May 17th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($0.03). The company had revenue of $1.55 million for the quarter, compared to analyst estimates of $0.48 million. Cue Biopharma had a negative return on equity of 56.24% and a negative net margin of 1,168.14%. As a group, analysts anticipate that Cue Biopharma, Inc. will post -1.47 earnings per share for the current year.

Separately, Robert W. Baird reissued a “buy” rating and issued a $28.00 price target on shares of Cue Biopharma in a report on Thursday, May 20th.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a fusion protein biologic that is in Phase I clinical trials designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.

Read More: What is the significance of the death cross?

Institutional Ownership by Quarter for Cue Biopharma (NASDAQ:CUE)

Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.